Clin Exp Rheumatol
-
Randomized Controlled Trial Comparative Study Clinical Trial
Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever.
1) To compare the sensitivity of serum amyloid A protein (A-SAA) and other acute phase proteins (APPs) in determining subclinical inflammation in patients with familial Mediterranean fever (FMF) during an attack-free period; 2) to define those clinical, laboratory features that may modify the A-SAA level; and 3) to evaluate the effect of an increase in the colchicine dose on the A-SAA level. ⋯ Subclinical inflammation continues during an attack-free period in FMF patients. A-SAA was the best marker of subclinical inflammation. Patients who are homozygous or compound heterozygotes of MEFV mutations had higher A-SAA levels. An increase in the colchicine dose resulted in a dramatic decrease in A-SAA and an increase in hemoglobin level. These findings favor the use of A-SAA in drug monitoring.
-
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Bath Ankylosing Spondylitis Functional Index (BASFI) and the Dougados Functional Index (DFI) are the most commonly used instruments to measure disease activity and functioning in ankylosing spondylitis (AS). The aim of this study was to translate, adapt and validate these instruments into the Spanish language. ⋯ The Mexican Spanish versions of the BASDAI, BASFI, and DFI showed adequate reliability, validity and responsiveness to clinical change. These instruments can be used in the clinical evaluation of Spanish-speaking patients with AS.
-
Comparative Study
Validation of an Italian version of the Fibromyalgia Impact Questionnaire (FIQ-I).
To validate a translated Italian version of the Fibromyalgia Impact Questionnaire (FIQ). ⋯ The Italian FIQ is a reliable and valid instrument for detecting and measuring functional disability and health status in Italian patients with FM.